Personalis Q4 2024 Earnings Report $3.82 +0.23 (+6.41%) As of 03/12/2025 04:00 PM Eastern Earnings HistoryForecast Personalis EPS ResultsActual EPS-$0.23Consensus EPS -$0.32Beat/MissBeat by +$0.09One Year Ago EPSN/APersonalis Revenue ResultsActual Revenue$16.80 millionExpected Revenue$15.48 millionBeat/MissBeat by +$1.33 millionYoY Revenue GrowthN/APersonalis Announcement DetailsQuarterQ4 2024Date2/27/2025TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPSNL Earnings History Remove Ads Personalis Earnings HeadlinesFY2029 EPS Estimates for Personalis Cut by HC WainwrightMarch 5, 2025 | americanbankingnews.comNew Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence DetectionMarch 3, 2025 | businesswire.comWe recommended Palantir in 2021, now we’re recommending this...The International Energy Agency says, AI already uses as much energy as a small country - like Germany or Saudi Arabia. And AI's energy demand is set to double in the coming years. Meaning it will soon consume more energy than countries like Sweden or Japan. And consider that we're still in the very early stages of the AI wave. According to government data, only 5% of US companies have started to utilize AI yet.March 13, 2025 | Behind the Markets (Ad)Personalis Reports 2024 Growth and Strategic PartnershipsFebruary 27, 2025 | tipranks.comPersonalis sees FY25 revenue $80M-$90M, consensus $84.65MFebruary 27, 2025 | markets.businessinsider.comPersonalis sees Q1 revenue $17M-$18M, consensus $16.25MFebruary 27, 2025 | markets.businessinsider.comSee More Personalis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Personalis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Personalis and other key companies, straight to your email. Email Address About PersonalisPersonalis (NASDAQ:PSNL) develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.View Personalis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles These 3 Q1 Earnings Winners Will Go HigherAnalysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before Earnings Upcoming Earnings PDD (3/19/2025)Micron Technology (3/20/2025)Accenture (3/20/2025)FedEx (3/20/2025)NIKE (3/20/2025)Cintas (3/26/2025)Paychex (4/1/2025)Bank of New York Mellon (4/11/2025)BlackRock (4/11/2025)JPMorgan Chase & Co. (4/11/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
